CliffBio
small molecule

VIBERZI

ELUXADOLINE

Loss of exclusivityMarch 2033latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameVIBERZI
Active ingredientELUXADOLINE
Strength75MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2015
Marketing statusRX

Listed patents

PatentExpiresType
11090291March 2033product
11311516March 2033product
9675587March 2033product
11229627March 2033product
11160792March 2033product
10188632March 2033product
12097187March 2033use U-3475
11007179March 2033product
7741356May 2029substance, product
9364489July 2028use U-1709
9789125July 2028product
8691860July 2028substance
9115091July 2028substance, product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIBERZI patent cliff — loss of exclusivity March 2033 | CliffBio